Basic information Indications and Usage Mechanisms of Action Safety Related Supplier
ChemicalBook >  Product Catalog >  API >  Antineoplastic agents >  Tinib Antineoplastic drugs >  Lapatinib


Basic information Indications and Usage Mechanisms of Action Safety Related Supplier
Lapatinib Basic information
Lapatinib Chemical Properties
  • Boiling point:750.7±60.0 °C(Predicted)
  • Density 1.381±0.06 g/cm3(Predicted)
  • storage temp. Keep in dark place,Sealed in dry,2-8°C
  • pka6.34±0.19(Predicted)
  • CAS DataBase Reference231277-92-2(CAS DataBase Reference)
Safety Information
Lapatinib Usage And Synthesis
  • Indications and UsageLapatinib is a drug targeting breast cancer developed by British GlaxoSmithKline Co.
    Human ErbB receptors belong to the type I tyrosine kinase (TK) receptor family, including ErbB1 (EGFR), ErbB2 (HER2), ErbB3 (HER3), and ErbB4 (HER4). The ErbB-1 (EGFR) and ErbB-2 (HER-2) receptors are often overexpressed or otherwise altered in cancer patients. Human epidermal growth factor receptor 2 (ErbB-2, HER-2) is known to be a human oncogene closely related with breast cancer. Its high expression in breast cancer often predicts lymph node metastasis and poor tumor differentiation, with poor prognosis. HER-2 is one of the target molecules for breast cancer-specific therapy. Lapatinib can act simultaneously on both Her-1 Her-2. The biological effects of this method inhibiting the proliferation and growth of tumor cells are much larger than only acting on one target. The combination of Lapatinib with Capecitabine is used to treat patients with advanced or metastatic breast cancer with overexpression of human epidermal receptor2, already treated with anthracyclines, paclitaxel, and trastuzumab. Clinical trials have shown that Lapatinib also effectively treats HER2-type cancer patients with Herceptin resistance.
  • Mechanisms of ActionLapatinib is a tyrosine kinase inhibitor which can effectively inhibit the tyrosine kinase activity of human epidermal growth factor receptors 1 and 2 (ErbB1, ErbB2). It can uniquely act in a variety of ways, ensuring that breast cancer cells cannot receive growth signals. It inhibits intracellular EGFR (ErbB-1) and HER2 (ErbB-2) ATP sites, preventing tumor cell phosphorylation and activation, blocking down-regulation signals through the homogeneity and heterogeneity of EGFR (ErbB-1) and HER2 (ErbB-1) dimerization.
  • DescriptionLapatinib, a new member of the 4-anilinoquinazoline class of RTK inhibitors (RTKIs), was launched as an oral treatment for breast cancer. Lapatinib has dual affinity for EGFR and HER2 tyrosine kinases. It is indicated in combination with capecitabine for treating patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Previously marketed drugs from the 4-anilinoquinazoline class include erlotinib (Tarceva) and gefitinib (IressaTM), both of which are indicated for treating non-small-cell lung cancer (NSCLC). As with erlotinib and gefitinib, To Market, To Market 2007 475 lapatinib is an ATP-competitive kinase inhibitor. It inhibits the tyrosine kinase activity EGFR and HER-2 with apparent Ki values of 3 and 13 nM, respectively, and has slow off-rate kinetics (t1/2X300 min).
    In addition, dividing the daily dose of lapatinib results in approximately 2-fold higher exposure at steady state compared to the same total dose administered once daily.
    The chemical synthesis of lapatinib entails the condensation of 4-chloro-6-iodoquinazoline and 3-chloro-4-(3-fluorobenzyloxy)aniline to produce a diaryl amine intermediate followed by Stille coupling of the iodo group with 5-dioxolanyl-2-(tributylstannyl)furan and subsequent acid hydrolysis of the cyclic ketal to the corresponding aldehyde. Finally, reductive amination of the aldehyde intermediate with 2-(methanesulfonyl) ethylamine in the presence of sodium triacetoxyborohydride produces lapatinib. .
  • OriginatorGSK (US)
  • UsesLapatinib Ditosylate (GW572016, GW2016, Tykerb, Tyverb) is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively.
  • UsesLapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively.
  • Usesantineoplastic, tyrosine kinase inhibitor
  • UsesAn antineoplastic agent used in breast cancer research
  • brand nameTykerb
Lapatinib(231277-92-2)Related Product Information
  • Company Name:Guangzhou Isun Pharmaceutical Co., Ltd Gold
  • Tel:18927568969 020-39119399-
  • Company Name:Target molecule Corp. Gold
  • Tel:857-239-0968
  • Company Name:Guangzhou Tomums Life Science Co., Ltd. Gold
  • Tel:18902330969 020-31155029-
  • Company Name:Shandong KangMeiLe Pharmaceutical Co., Ltd. Gold
  • Tel:15863163769 0531-55721656-
  • Company Name:Wuhan belka pharmaceutical co., LTD Gold
  • Tel:17798255750